The clinical manifestations of SLE are heterogeneous, so the diagnosis can be challenging.[8] Therapeutic strategies mainly involve immunoregulation and immunosuppression with the aim of relieving the specific organ manifestations and achieving low disease activity.[9] AHA is a severe life-threatening autoimmune disease resulting from autoantibodies directed against coagulation factors, the most common being FVIII. This evidence concerns the gene F8 and systemic lupus erythematosus.